Plain language summary EuroSpA publication 1.4, interview with Louise Linde:
This is a plain language summary interview of postdoctoral researcher Louise Linde, MD, PhD, explaining the key content of the scientific publication from EuroSpA by Linde et. al:
“Second and third TNF inhibitors in European patients with axial spondyloarthritis: effectiveness and impact of the reason for switching”.
You can read the original manuscript published in Rheumatology in 2023 here: https://doi.org/10.1093/rheumatology/kead494
The original study was financially sponsored by Novartis.
Plain language summary EuroSpA publication 4.1, interview with Louise Linde:
This is a plain language summary interview of postdoctoral researcher Louise Linde, MD, PhD, explaining the key content of the scientific publication from EuroSpA by Linde, Ørnbjerg, Georgiadis et. al:
“Predictors of DAPSA28 remission in patients with psoriatic arthritis initiating a first TNF inhibitor: results from 13 European registries”.
You can read the original manuscript published in Rheumatology in 2023 here: https://doi.org/10.1093/rheumatology/kead284
The original study was financially sponsored by Novartis.
Editor’s Picks Spotlight, interview with Lykke Ørnbjerg on EuroSpA publication 2.1:
This is a editors pick interview with postdoctoral researcher Lykke Midtbøll Ørnbjerg, MD, PhD, explaining the key content of the scientific publication from EuroSpA by Ørnbjerg et. al:
“Patient-Reported Outcomes (PROs) and PRO Remission Rates in 12,262 Biologic-Naïve Patients With Psoriatic Arthritis Treated With Tumor Necrosis Factor Inhibitors in Routine Care”.
You can read the original manuscript published in The Journal of Rheumatology in 2024 here:
https://www.jrheum.org/content/early/2024/02/09/jrheum.2023-0764
The original work was financially sponsored by Novartis.
Plain language summary EuroSpA publication 2.2, interview with Lykke Ørnbjerg:
This is a plain language summary interview of postdoctoral researcher Lykke Midtbøll Ørnbjerg, MD, PhD, explaining the key content of the scientific publication from EuroSpA by Ørnbjerg, Rugbjerg et. al:
“One-Third of European Patients with Axial Spondyloarthritis Reach Pain Remission with Routine Care Tumor Necrosis Factor Inhibitor Treatment”.
You can read the original manuscript published in The Journal of Rheumatology in 2023 here: https://www.jrheum.org/content/early/2023/01/10/jrheum.220459.long
The original study was financially sponsored by Novartis.